Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress
Clarametyx Biosciences announced key changes to its leadership team aimed at accelerating its therapeutic and vaccine pipeline as well as advancing corporate development initiatives12910.
Steve St. Onge, PharmD, MBA was promoted to Chief Business Officer, expanding his prior role as Senior Vice President of Corporate Development, and will oversee strategic priorities including business development and financing12.
Brendan Doran, PharmD, joined Clarametyx as Senior Vice President of Clinical Development, bringing over 15 years of experience in advancing novel therapies across infectious disease, immunology, and rare diseases12.
These appointments are part of Clarametyx's focus on progressing its clinical pipeline, with advanced-stage studies in therapies for biofilm-driven chronic respiratory diseases such as cystic fibrosis12.
Clarametyx’s pipeline includes CMTX-101, currently in a Phase 2 study for cystic fibrosis-related infections, and CMTX-301, which is in preclinical development2.
The leadership changes follow recent regulatory and financial milestones for the company, including FDA Fast Track and QIDP designations for CMTX-101 and completion of funding tranches to support ongoing pipeline activities5.
Sources:
1. https://www.biospace.com/press-releases/clarametyx-biosciences-strengthens-leadership-team-to-accelerate-pipeline-and-corporate-development-progress
2. https://www.businesswire.com/news/home/20251020791178/en/Clarametyx-Biosciences-Strengthens-Leadership-Team-to-Accelerate-Pipeline-and-Corporate-Development-Progress
5. https://clarametyx.com/clarametyx-biosciences-announces-fda-grant-of-fast-track-and-qualified-infectious-disease-product-designations-for-cmtx-101/